Sergey Menis

List of Publications by Year
in descending order

37 papers	5,496 citations	172207 29 h-index	360668 35 g-index
39 all docs	39 docs citations	39 times ranked	4794 citing authors

#	Article	IF	Citations
1	Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates. Biomaterials, 2021, 275, 120868.	5.7	16
2	Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation InÂVivo. Immunity, 2020, 53, 548-563.e8.	6.6	149
3	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22920-22931.	3.3	42
4	Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. Npj Vaccines, 2020, 5, 72.	2.9	39
5	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structureâ€Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. Advanced Science, 2020, 7, 1902802.	5.6	30
6	Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nature Medicine, 2020, 26, 430-440.	15.2	172
7	Nanoparticle Vaccines: In Vivo Assembly of Nanoparticles Achieved through Synergy of Structureâ€Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity (Adv.) Tj ETQq1 1 0.784314 rgBT /Ov	5.6	1
8	Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16473-16478.	3.3	141
9	Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. Immunity, 2019, 51, 141-154.e6.	6.6	71
10	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. Molecular Therapy, 2019, 27, 2080-2090.	3.7	58
11	Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. Cell, 2019, 177, 1153-1171.e28.	13.5	293
12	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science, 2019, 363, 649-654.	6.0	227
13	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. Immunity, 2018, 48, 133-146.e6.	6.6	274
14	Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Scientific Reports, 2018, 8, 16527.	1.6	69
15	Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. Nature Communications, 2018, 9, 3693.	5.8	124
16	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Science Translational Medicine, 2018, 10, .	5.8	113
17	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. Immunity, 2018, 49, 301-311.e5.	6.6	110
18	Glycoengineering HIV-1 Env creates â€˜superchargedâ€™ and â€˜hybridâ€™ glycans to increase neutralizing antibody potency, breadth and saturation. PLoS Pathogens, 2018, 14, e1007024.	2.1	22

#	Article	IF	Citations
19	Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nature Communications, 2017, 8, 14954.	5.8	176
20	Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. Virology, 2017, 505, 193-209.	1.1	36
21	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science, 2016, 353, 1557-1560.	6.0	147
22	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell, 2016, 166, 1459-1470.e11.	13.5	230
23	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell, 2016, 166, 1471-1484.e18.	13.5	198
24	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity, 2016, 45, 483-496.	6.6	335
25	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Reports, 2016, 16, 2327-2338.	2.9	216
26	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathogens, 2015, 11, e1004932.	2.1	141
27	Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science, 2015, 349, 156-161.	6.0	358
28	Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nature Communications, 2015, 6, 7479.	5.8	113
29	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. PLoS Computational Biology, 2015, 11, e1003973.	1.5	51
30	Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. Science Translational Medicine, 2014, 6, 236ra63.	5.8	160
31	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. AIDS Research and Human Retroviruses, 2014, 30, A25-A26.	0.5	0
32	Investigating Epitope Exposure on Native Trimers. AIDS Research and Human Retroviruses, 2014, 30, A35-A35.	0.5	0
33	Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. Science, 2013, 340, 711-716.	6.0	680
34	Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. Journal of Experimental Medicine, 2013, 210, 655-663.	4.2	275
35	An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells. PLoS ONE, 2013, 8, e67309.	1.1	4
36	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature, 2012, 490, 417-420.	13.7	405

#	Article	IF	Citations
37	A Chimeric HIV-1 Envelope Glycoprotein Trimer with an Embedded Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Domain Induces Enhanced Antibody and T Cell Responses. Journal of Biological Chemistry, 2011, 286, 22250-22261.	1.6	15